Charts of the Day: Akorn, Henry Schein, Merck

Fresenius no longer buying Akorn in wake of breach allegations; Henry Schein merging its Animal Health business and with startup Vets First Choice; Merck shares rallying following rare double-upgrade by Goldman to Conviction Buy